Skip to main content
MyDeficiencies

Etelcalcetide

calcimimetic, calcium-sensing receptor agonist (IV peptide)

Also sold as Parsabiv.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Etelcalcetide has one dominant, extremely well-documented depletion effect, and like its oral relative cinacalcet it is not subtle: by allosterically activating the parathyroid calcium-sensing receptor (CaSR), it directly suppresses PTH and, through that, lowers serum calcium in the large majority of treated hemodialysis patients. Pooled placebo-controlled trial data in the label show 64% of treated patients had a "blood calcium decreased" adverse event (vs 10% placebo), 79% developed a corrected calcium below 8.3 mg/dL (vs 19% placebo), and 27% developed severe hypocalcemia below 7.5 mg/dL (vs 5.5% placebo). The drug-specific DUET trial (Japan, n=124) independently confirms this at 74.4% incidence and shows a clinically important management detail: pairing etelcalcetide with active vitamin D corrected calcium far more safely than pairing it with oral calcium alone (0% vs 12.2% severe hypocalcemia). This is graded red. A real but bounded phosphate reduction (18% of patients fell below the lower normal limit vs 8.2% on placebo; frank hypophosphatemia 1% vs 0.2%) is graded orange, largely overlapping with the drug's intended treatment goal in secondary hyperparathyroidism. A small, labeled increase in hyperkalemia (4% vs 3%) is graded yellow: real per the label, but small in magnitude, unestablished in mechanism, and running in the excess/retention direction rather than depletion.

calcimimetic, calcium-sensing receptor agonist (IV peptide) · ATC H05BX04 · also sold as Parsabiv · reviewed 2026-09-26. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Etelcalcetide in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
severe: 2+ independent tier A sources, this drug in the studied cohort, direct measurement, consistent direction, clinically meaningful magnitude, named mechanism, no substantial contradicting tier A evidence.
Orange — Moderate
moderate: 1+ tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, frequency, or a functional rather than circulating measure.
Yellow — Low
low/theoretical: mechanistic plausibility only (tier B), or class extrapolation (tier C); also used for context flags and for reverse-direction/protective findings.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: no tier B/C evidence to support even yellow, and no circulating claim to rebut as white; a disclosed gap in the literature or in what could be accessed during this review, never reworded as reassurance.

What the research found

Calcium

Red — Severe

See study details

Etelcalcetide directly and predictably lowers serum calcium in the large majority of treated hemodialysis patients, with a well-established mechanism and explicit label instructions to stop the drug at defined thresholds.

Full detail and limits

What the grade means here: severe: 2+ independent tier A sources, this drug in the studied cohort, direct measurement, consistent direction, clinically meaningful magnitude, named mechanism, no substantial contradicting tier A evidence. Red

Limits on what this shows

  • Key negative/null findings: None found contradicting the direction or frequency of the effect. The DUET trial's active-vitamin-D-co-therapy result is a management finding that reduces severity, not evidence against occurrence.
  • At-risk subgroups: Congenital long QT syndrome or a family history of sudden death raises the stakes of any hypocalcemic episode via QT prolongation. Unlike cinacalcet's EVOLVE trial, no etelcalcetide-specific demographic predictor analysis (baseline PTH, BMI, region, etc.) for hypocalcemia risk was located during this review; this is noted as a gap rather than assumed absent.
  • Counter-evidence on record: None found that contradicts direction or frequency.

Regulatory status

U.S. labeling requires monitoring corrected serum calcium within 1 week of initiation or dose adjustment, then every 4 weeks; the drug must be stopped if corrected calcium falls below 7.5 mg/dL or symptoms of hypocalcemia develop.

Population evidence

Label pooled placebo-controlled trials (N=503 PARSABIV, N=513 placebo): "blood calcium decreased" adverse event 64% vs 10%; symptomatic hypocalcemia 7% vs 0.2%; corrected calcium <8.3 mg/dL in 79% vs 19%; corrected calcium <7.5 mg/dL (severe) in 27% vs 5.5%. The drug-specific DUET trial (randomized, n=124 Japanese hemodialysis patients, 12 weeks) independently confirms this: 74.4% of etelcalcetide-treated patients developed hypocalcemia, and severe hypocalcemia (corrected calcium <7.4 mg/dL) occurred in 12.2% of patients co-treated with oral calcium versus 0% of patients co-treated with active vitamin D (p=0.018 for fewer hypocalcemic visits with vitamin D co-therapy).

Mechanism

Named: the peptide allosterically activates the parathyroid CaSR, increasing its sensitivity to extracellular calcium and suppressing PTH secretion within 30 minutes of dosing, which reduces PTH-driven bone resorption and calcitriol-mediated intestinal calcium input.

Counter-evidence held on record

This is a depletion-direction effect, not a retention effect: calcium supplementation or active vitamin D co-therapy (not restriction) is the monitoring response, and only under prescriber supervision given the QT-prolongation and seizure risk of severe hypocalcemia. Do not use hypocalcemia values here to suggest calcium intake changes without a prescriber; mild, asymptomatic hypocalcemia is expected and often managed by dose adjustment rather than by treating the calcium value in isolation.

Phosphate

Orange — Moderate

See study details

Etelcalcetide produces a real but bounded reduction in serum phosphate in hemodialysis patients with secondary hyperparathyroidism, a change that substantially overlaps with the intended therapeutic goal rather than being a pure incidental depletion.

Full detail and limits

What the grade means here: moderate: 1+ tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, frequency, or a functional rather than circulating measure. Orange

Limits on what this shows

  • Key negative/null findings: Frank hypophosphatemia was recorded in only 1% of treated patients, a small absolute rate relative to the scale of the calcium signal.
  • At-risk subgroups: Patients co-treated with phosphate binders or with low baseline phosphate are the plausible at-risk group for over-suppression, though this was not directly quantified in the sources reviewed. A meta-analysis of etelcalcetide-versus-placebo trials (Zhu et al, Clinical Nephrology 2020) likely bears on this but could not be opened during this review (confirmed closed-access via the Unpaywall API); it is listed in Sources, not used as evidence.
  • Counter-evidence on record: The label frames phosphate reduction alongside falling PTH and calcium as a treatment-response marker, not an isolated adverse depletion signal.

Regulatory status

Phosphate is a routine monitoring parameter alongside calcium and PTH; no phosphate-specific boxed or warnings-level language.

Population evidence

Label pooled placebo-controlled trials (same N=503/513 cohort as the Calcium entry): 18% of PARSABIV patients versus 8.2% of placebo patients had at least one measured phosphorus level below the lower normal limit; frank hypophosphatemia was recorded as an adverse reaction in 1% versus 0.2%.

Mechanism

Named but indirect: PTH suppression reduces PTH-driven bone resorption, and since resorption is normally a larger contributor to serum phosphate than PTH's phosphaturic effect in this population, net serum phosphate falls as PTH falls. This mirrors the disease-treatment goal in secondary hyperparathyroidism (KDIGO-aligned phosphate control), not a novel adverse mechanism.

Counter-evidence held on record

Do not present this as a phosphate deficiency risk in isolation from treatment context; in secondary hyperparathyroidism, a falling phosphate alongside falling PTH is usually the desired clinical outcome. Flag only for patients on concurrent phosphate binders or with low baseline phosphate, and only as a monitoring reminder, not a supplementation prompt.

Potassium

Yellow — Low

See study details

The label records a small, real increase in hyperkalemia incidence with etelcalcetide, but the magnitude is modest, no mechanism connecting CaSR agonism or PTH suppression to potassium handling has been documented, and hemodialysis patients carry substantial baseline hyperkalemia risk independent of any study drug.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (tier B), or class extrapolation (tier C); also used for context flags and for reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null findings: The absolute difference (1 percentage point) is small; no drug-specific study was found either confirming or excluding a causal mechanism.
  • At-risk subgroups: Not established beyond the general hemodialysis population.
  • Counter-evidence on record: None found either direction; this is a low-confidence signal recorded here rather than omitted, per Hard Rule 1.

Regulatory status

Listed as a laboratory-abnormality adverse reaction below the label's main 5%-incidence table; not addressed in warnings and precautions.

Population evidence

Label pooled placebo-controlled trials (same N=503/513 cohort): hyperkalemia 4% (PARSABIV) versus 3% (placebo). No drug-specific study investigating a potassium mechanism was found; a Crossref search for etelcalcetide plus hyperkalemia/potassium returned only generic hyperkalemia literature with no etelcalcetide or calcimimetic relevance.

Mechanism

Not established. No documented pathway links CaSR agonism or PTH suppression to renal or cellular potassium handling for this drug; hemodialysis patients have substantial baseline hyperkalemia risk from residual renal impairment, dietary intake, and interdialytic shifts, which plausibly accounts for some background variability between trial arms independent of any drug effect.

Counter-evidence held on record

This is an excess/retention-direction signal, not a deficiency: it must never be presented as a reason to increase potassium intake, and the small, mechanistically unestablished magnitude does not by itself justify potassium restriction beyond the dietary counseling hemodialysis patients already receive.

Vitamin D

Yellow — Low

See study details

Because PTH is the physiological driver of renal calcitriol synthesis, etelcalcetide's confirmed PTH suppression creates a plausible mechanism for reduced 1,25-dihydroxyvitamin D production, but no study measuring this directly was found, and the mechanism has essentially no room to operate given that etelcalcetide is approved only for hemodialysis-dependent CKD, where native renal 1-alpha-hydroxylase activity is already minimal.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (tier B), or class extrapolation (tier C); also used for context flags and for reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null findings: None found either way; this is a measurement gap layered on a mechanism whose real-world relevance is doubly limited by the drug's exclusively dialysis-dependent indication.
  • At-risk subgroups: None identifiable, since the drug is not approved outside the anephric hemodialysis population.
  • Counter-evidence on record: The population-applicability caveat above is itself the main counter-evidence: the mechanism's premise (functioning renal 1-alpha-hydroxylase) is essentially absent across this drug's approved population.

Regulatory status

Not addressed directly in labeling. The drug-specific DUET trial found that pairing etelcalcetide with active vitamin D sterol controlled calcium far more safely than pairing it with oral calcium (0% vs 12.2% severe hypocalcemia; fewer hypocalcemic visits, p=0.018), which is a clinician-driven co-therapy interaction, not direct evidence of an etelcalcetide effect on endogenous vitamin D synthesis.

Population evidence

No study measuring 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D before/after etelcalcetide specifically was found.

Mechanism

Present in principle (hormonal-axis mechanism): PTH stimulates renal 1-alpha-hydroxylase, which converts 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D, and etelcalcetide's PTH-suppressing effect is itself Tier A for this drug. However, unlike cinacalcet (which also carries non-dialysis indications where native kidney function is preserved), etelcalcetide's only approved indication is hemodialysis-dependent CKD, where this pathway is minimal to absent in essentially the entire treated population.

Counter-evidence held on record

Do not present as an established vitamin D depletion effect. This entry is mechanism-only and is not clinically relevant for the anephric hemodialysis patients who make up this drug's entire labeled population; those patients receive vitamin D sterols exogenously per separate clinical protocols regardless of any endogenous-synthesis question.

Magnesium - theoretical renal CaSR mechanism, foreclosed further than for cinacalcet by an exclusively anephric population

Yellow — Low

See study details

The calcium-sensing receptor's well-established role in renal tubular magnesium handling gives any potent CaSR agonist, including etelcalcetide, a theoretical magnesium-wasting mechanism, but this pathway requires functioning renal tubules that are essentially absent across etelcalcetide's exclusively hemodialysis-dependent population, and the one drug-specific measurement located could not be opened.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (tier B), or class extrapolation (tier C); also used for context flags and for reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null findings: Cinacalcet's own n=6 study is a null finding for magnesium, carried here as the class-level result rather than an etelcalcetide-specific one.
  • At-risk subgroups: None identifiable for etelcalcetide specifically; the mechanism's premise (residual tubular function) is essentially absent across this drug's approved population.
  • Counter-evidence on record: The population-applicability caveat above is itself the main counter-evidence, mirroring the Vitamin D entry's reasoning: the mechanism's premise is largely foreclosed in the population where etelcalcetide is used.

Regulatory status

Not addressed in etelcalcetide labeling; magnesium is not a labeled monitoring parameter.

Population evidence

No etelcalcetide-specific magnesium result could be confirmed, but a real, drug-specific measurement exists: the DUET trial (Itano et al, Kidney International Reports 2020; n=124 Japanese hemodialysis patients) explicitly reports a "change in magnesium in a linear mixed model" as Supplementary Figure S4. The main article text was opened directly for this revision and confirms the measurement was made, but the supplementary PDF itself returned a robots.txt block on every fetch attempt, so the direction and significance of the etelcalcetide-arm magnesium change remain unconfirmed rather than assumed null. Class-level: cinacalcet's own drug-specific study (peritoneal dialysis patients with residual renal function, n=6, 2 months) found serum magnesium fell numerically (2.2 to 2.0 mg/dL) but not significantly, with urinary magnesium excretion unchanged.

Mechanism

Present at the receptor level (mechanism class C, renal tubular handling), and independently confirmed for this revision as general CaSR physiology rather than a cinacalcet-specific claim: the calcium-sensing receptor is expressed in the thick ascending limb of the loop of Henle, where its activation reduces paracellular reabsorption of both calcium and magnesium (established physiology references: Schlingmann, Calcium-Sensing Receptor and Magnesium, 2007; Toka, Pollak and Houillier, Calcium Sensing in the Renal Tubule, Physiology 2015). This is receptor-level, not molecule-specific, physiology, so it is mechanistically available to etelcalcetide as much as to cinacalcet regardless of the IV-versus-oral route difference. However, the pathway requires functioning renal tubules to operate, and etelcalcetide's only approved population is hemodialysis-dependent CKD, where native tubular function is minimal to absent in essentially the entire treated population, a stronger foreclosure than for cinacalcet, which is also used in peritoneal dialysis patients with residual renal function and in non-dialysis primary hyperparathyroidism.

Counter-evidence held on record

Do not present as an established magnesium-wasting effect. This entry exists to record mechanistic plausibility for future review pending access to the DUET trial's own magnesium data, not to support a supplementation recommendation.

  • Schlingmann KP. Calcium-Sensing Receptor and Magnesium. — Book chapter, 2007. DOI 10.1007/978-1-84628-483-0_22. Established, receptor-level (not drug-specific) physiology reference confirming CaSR's role in renal tubular magnesium handling; used as class-generic mechanism support for the Magnesium entry.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden - class-level lead independently verified as receptor-generic, not cinacalcet-specific

Yellow — Low

See study details

A calcium-sensing-receptor-dependent mitochondrial biogenesis pathway shown for cinacalcet in diabetic kidney tissue was independently re-verified here as genuinely receptor-mediated rather than specific to cinacalcet's own chemistry, making it a legitimate, if unconfirmed, class-level lead for etelcalcetide; a separate cinacalcet mitochondrial-toxicity finding was also checked and found to be explicitly CaSR-independent, so it does not transfer.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (tier B), or class extrapolation (tier C); also used for context flags and for reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null findings: No etelcalcetide-specific data confirming or refuting this exists; this is disclosed as class-level extrapolation, not drug-specific confirmation.
  • At-risk subgroups: Not established for etelcalcetide.
  • Counter-evidence on record: The bEND.3 finding, which might otherwise have looked like a second class-level mitochondrial signal, was independently checked and found to be CaSR-independent and therefore not applicable to etelcalcetide; this is recorded to prevent it being mistakenly carried forward as class support.

Regulatory status

Not addressed in labeling.

Population evidence

No etelcalcetide-specific mitochondrial study was found despite Crossref and PubMed queries. Two cinacalcet-specific studies were independently opened and checked for class transferability. (1) Cell Death and Disease, 2018: C57BLKS/J db/db diabetic mice (n=8/group), cinacalcet 10 mg/kg in diet for 12 weeks, found increased renal CaMKKbeta, phospho-LKB1, phospho-AMPK, and PGC-1alpha (a mitochondrial biogenesis regulator), reversed by the intracellular calcium chelator BAPTA-AM, with the paper explicitly framing cinacalcet as one member of a broader calcimimetic class acting through CaSR-mediated calcium mobilization, not through unique cinacalcet chemistry. (2) A separate in vitro study (mouse brain microvascular bEND.3 endothelial cells, cinacalcet 18-30 uM) found mitochondrial membrane depolarization and cell death, but this effect was explicitly shown to be unaffected by NPS 2143, a CaSR negative allosteric modulator, meaning it is CaSR-independent, off-target cytotoxicity tied to cinacalcet's own small-molecule structure at supra-therapeutic concentrations, not a receptor-level class effect, and is not carried forward as a lead for etelcalcetide.

Mechanism

Present at the receptor level (mechanism class E), and independently confirmed here as CaSR-signaling-generic: the CaMKKbeta-LKB1-AMPK-PGC-1alpha cascade is triggered by intracellular calcium mobilization following CaSR activation, and etelcalcetide, though it binds a different site on the receptor (a covalent, reversible interaction at the extracellular domain versus cinacalcet's transmembrane-domain allosteric binding), is also a potent systemic CaSR agonist that raises intracellular calcium signaling in CaSR-expressing tissue. The specific tissue context of the source study, diabetic kidney parenchyma, is a caveat for etelcalcetide's exclusively hemodialysis-dependent, largely anephric population, similar to the Vitamin D entry's reasoning, but the underlying calcium-signaling cascade is not restricted to kidney tissue and could plausibly operate in other CaSR-expressing tissues (vasculature, cardiac, immune cells) reached by etelcalcetide's systemic exposure.

Counter-evidence held on record

Do not present as an established mitochondrial effect of etelcalcetide. This is an unverified class-level extrapolation from an animal kidney model of a different calcimimetic, not a drug-specific finding, and should not be used to suggest either mitochondrial harm or benefit at approved etelcalcetide dosing in humans.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress - class-level signal from two cinacalcet studies, mechanism not resolved as receptor-generic or molecule-specific

Yellow — Low

See study details

Two independent human studies found cinacalcet reduces oxidative stress markers in hemodialysis patients, but neither study, nor this independent review, could establish whether the effect is calcium-sensing-receptor-mediated, which would plausibly extend to etelcalcetide, or a property specific to cinacalcet's own molecular structure, which would not.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (tier B), or class extrapolation (tier C); also used for context flags and for reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null findings: Neither study used a randomized placebo comparator (both are observational/before-after designs), so regression to the mean or other unmeasured confounders cannot be excluded even for cinacalcet itself.
  • At-risk subgroups: Not established for etelcalcetide; the source population in both studies is hemodialysis patients with secondary hyperparathyroidism, the same population etelcalcetide treats.
  • Counter-evidence on record: The unresolved receptor-versus-structure question is itself the main limitation on extending this to etelcalcetide; no study has tested a non-cinacalcet CaSR agonist for this effect.

Regulatory status

Not addressed in etelcalcetide labeling; both source studies concern cinacalcet, not etelcalcetide.

Population evidence

No etelcalcetide-specific oxidative-stress study was found. Two cinacalcet studies were independently re-opened for this revision. Diri et al (International Urology and Nephrology, 2014, n=42 cinacalcet-treated hemodialysis patients vs 38 matched controls, 6 months): oxidative stress markers improved; the paper's own conclusion states the benefit "may be related rather to the direct action of cinacalcet than to the serum PTH concentration decrease," without further specifying a receptor-level or structural basis. A second study (Nephron, 2018, n=58 hemodialysis patients, before/after 6 months): advanced oxidation protein products fell (152 to 49 umol/L, p<0.0001) and total antioxidant capacity rose (p=0.04); no significant correlation was found between the antioxidant change and PTH change, but a significant positive correlation was found with cinacalcet dose (r=0.30, p=0.02).

Mechanism

Unresolved, and this is disclosed rather than resolved in either direction. The dose correlation and the absence of a PTH correlation together rule out simple PTH-lowering as the explanation, but neither source establishes whether the residual effect is CaSR-receptor-mediated (supported in principle by separate literature showing CaSR activation on endothelium can induce nitric oxide production, a receptor-generic pathway that would extend to etelcalcetide) or a direct chemical property of cinacalcet's own aryl-alkylamine structure (which would not, since etelcalcetide is a structurally unrelated D-amino-acid peptide). Both papers' own language reads as ambiguous between these two readings rather than confirming either.

Counter-evidence held on record

This is a reverse-direction (potentially protective) signal if it transfers at all, not a deficiency, and it must never be presented as an established etelcalcetide effect or as a reason to avoid antioxidant-relevant nutrient support; the class-level mechanism question is genuinely unresolved.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No tier B or C evidence, and no circulating consumer claim, connecting etelcalcetide to copper status was found.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: The dual condition for ungraded is met. A Crossref query for etelcalcetide plus copper/trace element returned only unrelated geological, agricultural, and unrelated-drug trace-element literature, no etelcalcetide or calcimimetic relevance at all. Etelcalcetide's pharmacokinetics give no plausible mechanism either: it undergoes no hepatic metabolism at all, has no chelating chemistry, and is dosed intravenously, bypassing any gastrointestinal absorption-interference pathway entirely (a stronger case for exclusion than cinacalcet, which is at least orally absorbed). No consumer nutrient-depletion claim naming copper for etelcalcetide was located.

Iron

Not graded — disclosed evidence gap

See study details

No tier B or C evidence, and no circulating consumer claim, connecting etelcalcetide to iron status was found; the erythropoietin-resistance mechanism discussed under Oxygen delivery/utilization concerns red-cell production responsiveness, not iron status itself, and is not used here to avoid double-counting one signal as two findings.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: The dual condition for ungraded is met. A Crossref query for etelcalcetide plus iron/ferritin/hepcidin returned only generic iron-metabolism review literature with no etelcalcetide or calcimimetic relevance. No consumer or circulating claim connecting etelcalcetide to iron, ferritin, or hepcidin was located.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

Unlike oral cinacalcet, etelcalcetide reaches the gut lumen only minimally, and directly-opened preclinical evidence used as a class-level lead specifically found that the intestinal CaSR effect requires apical (luminal), not basolateral/systemic, exposure, weakening rather than supporting any class extrapolation to this drug.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: The dual condition for ungraded is met, with an unusually well-documented mechanistic reason for exclusion rather than a bare absence of searching. Etelcalcetide is given intravenously and only about 7% of a dose is recovered in urine and feces combined (as biotransformation products, not luminal parent drug), versus roughly 60% cleared by the dialyzer. A directly-opened preclinical source (JCI Insight, used as a cinacalcet class-level lead and independently verified here, not cited secondhand) found that cinacalcet applied only to the basolateral chamber of human colonic epithelial cells produced no antisecretory effect, and that apical (luminal) CaSR activation specifically drives the effect; a companion review (Frontiers in Physiology) confirms CaSR is present on both apical and basolateral enterocyte membranes but does not address whether systemic drug exposure activates the basolateral receptor in vivo, and reports no gut-microbiome composition or diversity data for any calcimimetic. No etelcalcetide-specific or class-level microbiome composition/diversity study was found, and no consumer claim connecting etelcalcetide to the gut microbiome was located.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Yellow — Low

See study details

A directly-verified parathyroidectomy series shows that sharply lowering PTH in secondary hyperparathyroidism can markedly raise erythropoietin and improve erythropoiesis, a mechanism directly relevant to etelcalcetide's own potent PTH-suppressing action, but no study has measured hemoglobin or erythropoietin responsiveness in etelcalcetide-treated patients specifically.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (tier B), or class extrapolation (tier C); also used for context flags and for reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null findings: None found; this is a data-thinness limitation rather than a contradicting result.
  • At-risk subgroups: Not established for etelcalcetide specifically beyond the severe-secondary-hyperparathyroidism-with-marrow-fibrosis population implied by the mechanism.
  • Counter-evidence on record: None found; note the evidence transfer here (surgery to a calcimimetic peptide) is indirect and should not be read as drug-specific confirmation.

Regulatory status

Not addressed in labeling.

Population evidence

No etelcalcetide-specific hemoglobin, hematocrit, or erythropoietin study was found. Directly opened: Ureña et al (Nephron; accessed via University of Regensburg repository abstract), a parathyroidectomy (PTx) series: in secondary hyperparathyroidism patients (n=23), serum erythropoietin rose from 23.1±4.8 mU/mL before PTx to 245±125 mU/mL fourteen days after, with a significant reticulocyte-count rise; in primary hyperparathyroidism patients (n=16), erythropoietin did not rise after PTx, yet reticulocyte count still increased, suggesting a component of the erythropoietic effect independent of erythropoietin itself. Dialysis patients given calcitriol for 14 days (n=14) showed decreased serum erythropoietin, a directionally separate finding about vitamin D rather than PTH. Two further parathyroidectomy-EPO-dosing titles (Trunzo et al, Surgery 2008; Yasunaga et al, American Journal of Surgery 2002) were located via bibliographic search but not independently opened in full text during this review; they are listed in Sources as corroborating titles only, not used as supporting evidence.

Mechanism

Proposed, not fully established for this drug: severe secondary hyperparathyroidism is associated with bone marrow fibrosis and erythropoietin resistance in the nephrology literature, and PTH lowering by any means, surgical in the Ureña data, is associated with improved erythropoiesis parameters. Etelcalcetide's core labeled action is potent, rapid PTH suppression, making the mechanism plausible, but the evidence base here is surgical (parathyroidectomy), not pharmacologic, so this is a mechanism-level extrapolation one step more indirect than a same-class drug comparison.

Counter-evidence held on record

Anemia in dialysis patients has many causes (iron status, erythropoietin dosing, inflammation, blood loss); do not attribute hemoglobin changes to etelcalcetide without excluding these. This is a mechanism-level, not a drug-specific, signal and should never be used to suggest withholding iron or erythropoietin-stimulating-agent workups.

ATP production - shares its source and reasoning with Mitochondrial burden, pathway marker only

Yellow — Low

See study details

The same CaSR-dependent CaMKKbeta-LKB1-AMPK-PGC-1alpha signaling shown for cinacalcet in diabetic kidney tissue is a mitochondrial-biogenesis pathway marker, not a direct ATP measurement, and the same class-level, receptor-generic reasoning and population caveats that apply to Mitochondrial burden apply here.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (tier B), or class extrapolation (tier C); also used for context flags and for reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null findings: No direct measurement of cellular ATP, oxygen consumption rate, or mitochondrial respiratory capacity was reported in the source study for cinacalcet, let alone for etelcalcetide; a pathway marker moving is not the same as ATP production changing.
  • At-risk subgroups: Not established in humans for either drug.
  • Counter-evidence on record: None found beyond the absence of a direct energetic-output measurement.

Regulatory status

Not addressed in labeling.

Population evidence

No etelcalcetide-specific or class-level ATP, oxygen-consumption-rate, or mitochondrial-respiratory-capacity measurement was found for any calcimimetic. The same Cell Death and Disease 2018 db/db mouse study cited under Mitochondrial burden is the only class-level lead, and it measured PGC-1alpha and upstream signaling, not ATP output itself.

Mechanism

Named at the pathway level and independently confirmed as CaSR-signaling-generic (see Mitochondrial burden for the BAPTA-AM verification); PGC-1alpha specifically drives mitochondrial biogenesis, which is upstream of, but not equivalent to, ATP output. Etelcalcetide's own systemic CaSR agonism makes this pathway mechanistically available in principle, subject to the same tissue-context and population caveats as Mitochondrial burden.

Counter-evidence held on record

Do not present as evidence that etelcalcetide increases cellular energy or ATP; the source measures upstream signaling and biogenesis markers in diabetic kidney tissue in mice treated with a different calcimimetic, not ATP itself, and shares its origin with the Mitochondrial burden entry above (see Overlap map).

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Coenzyme Q10

    Where it comes from: Generic "drug mugging" style depletion lists that attach CoQ10 loss to a broad range of chronic-disease medications, most legitimately statins (via shared mevalonate-pathway inhibition).

    Why it fails: Etelcalcetide undergoes no hepatic CYP metabolism at all and has no action on the mevalonate/HMG-CoA reductase pathway or any other CoQ10 biosynthetic step; it is dosed intravenously, so no oral/hepatic mechanism of the kind claimed for other drugs could apply even in principle. No drug-specific or class-level (calcimimetic) source was found supporting a mechanism or a measured effect.

  • Zinc

    Where it comes from: Generic mineral-depletion lists that attach zinc loss to many long-term prescription medications without drug-level stratification.

    Why it fails: No chelation, gastric-pH, or transporter-competition mechanism is possible for an intravenously administered peptide that never contacts the gastrointestinal tract at absorption-relevant concentrations, and no drug-specific or class-level study measuring zinc status with etelcalcetide was found despite a targeted search.

All references used above
  1. PARSABIV (etelcalcetide) injection, solution — prescribing information. — DailyMed, U.S. National Library of Medicine, Amgen Inc. Regulatory label, setid cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c, SPL version 15.
  2. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, code H05BX04 (etelcalcetide). — Regulatory/reference classification, confirming ATC code and parenteral defined daily dose (2.1 mg).
  3. Itano Y, Kato S, Tsuboi M, et al. A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial). — Kidney International Reports, 2020. Randomized, n=124 Japanese hemodialysis patients (118 analyzed), 12 weeks, three arms (etelcalcetide+vitamin D, etelcalcetide+calcium, control). DOI 10.1016/j.ekir.2020.09.010. Main text confirms the trial measured "change in magnesium in a linear mixed model," reported as Supplementary Figure S4.Supplementary Figure S4 (the magnesium result itself) could not be opened: the ScienceDirect supplementary-file host (ars.els-cdn.com) returned a robots.txt block on every fetch attempt during this revision. Direction and significance of the etelcalcetide-arm magnesium change are therefore unconfirmed; see the Magnesium entry.
  4. Ureña P, Eckardt KU, Sarfati E, et al. Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectomy. — Nephron, 1991. Parathyroidectomy series: secondary hyperparathyroidism (n=23), primary hyperparathyroidism (n=16), thyroid-surgery controls (n=3), plus a 14-day calcitriol/placebo dialysis substudy (n=14). Not etelcalcetide- or calcimimetic-specific; used here as mechanism-level physiology evidence for the PTH-erythropoiesis link. DOI 10.1159/000186596.Repository abstract-level access only; full PDF not independently fetched during this review.
  5. Repurposing calcium-sensing receptor agonist cinacalcet for treatment of CFTR-mediated secretory diarrheas. — JCI Insight. In vitro (T84, FRT, HBE cell lines) and in vivo (CD1 mice) preclinical study of cinacalcet, re-opened and independently verified for this dossier (not cited secondhand from the companion cinacalcet dossier). Used here as class-level mechanism evidence bearing on Gut microbiome risk, with the finding that basolateral-only exposure produced no effect.
  6. The extracellular calcium-sensing receptor in the intestine: evidence for regulation of colonic absorption, secretion, motility, and immunity. — Frontiers in Physiology. Class-level/receptor-physiology review, re-opened and independently verified for this dossier. Confirms apical and basolateral CaSR localization in enterocytes; reports no microbiome composition data for any calcimimetic.
  7. Block GA, Bushinsky DA, Cheng S, et al. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. — JAMA, 2017. PMID 28097356 (companion trial DOI 10.1001/jama.2016.19456).Could not be opened: JAMA Network returned a bot-verification (CAPTCHA) page on every fetch attempt during this review. Listed only; the label's pooled-trial figures used above are the independently-verified Tier A source for this population, not this unopened article.
  8. Block GA, Bushinsky DA, Cunningham J, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. — JAMA, 2017. DOI 10.1001/jama.2016.19468.Could not be opened: JAMA Network returned a bot-verification (CAPTCHA) page on every fetch attempt during this review. Listed only, not used as evidence.
  9. Khairallah P, Cherasard J, Sung J, et al. Changes in Bone Quality after Treatment with Etelcalcetide. — Clinical Journal of the American Society of Nephrology, 2023. PMID 37574661, DOI 10.2215/cjn.0000000000000254.Could not be opened: PubMed abstract page returned no content, and PMC (via the Unpaywall-listed URL) returned a reCAPTCHA challenge page on every attempt. Listed only, not used as evidence.
  10. Freitas P, Pereira L. Etelcalcetide: What we know eight years since its approval. — Nefrologia (Engl Ed), 2025. PMID 39986712.Could not be opened: PubMed abstract page returned a reCAPTCHA challenge on every fetch attempt during this review. Listed only, not used as evidence.
  11. Zhu Y, Ou J, Liu X, Xie Z. Etelcalcetide versus placebo for secondary hyperparathyroidism in patients receiving hemodialysis: A meta-analysis of randomized controlled trials. — Clinical Nephrology, 2020. DOI 10.5414/cn110110.Could not be opened: confirmed closed-access (no open-access location) via the Unpaywall API. Listed only, not used as evidence.
  12. Drueke TB. Role of secondary hyperparathyroidism in erythropoietin resistance. — Nephrology Dialysis Transplantation, 2002. DOI 10.1093/ndt/17.suppl_5.28.Could not be opened: confirmed closed-access (no open-access location) via the Unpaywall API. Listed only, not used as evidence.
  13. Trunzo JA, McHenry CR, Schulak JA, Wilhelm SM. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease. — Surgery, 2008. DOI 10.1016/j.surg.2008.07.026. Located via bibliographic (Crossref) metadata search only.Not independently opened in full text during this review; listed as a corroborating title only, not used as supporting evidence for any grade.
  14. Yasunaga C, Matsuo K, Yanagida T, et al. Early effects of parathyroidectomy on erythropoietin production in secondary hyperparathyroidism. — The American Journal of Surgery, 2002. DOI 10.1016/s0002-9610(01)00865-0. Located via bibliographic (Crossref) metadata search only.Not independently opened in full text during this review; listed as a corroborating title only, not used as supporting evidence for any grade.
  15. Zou C, Wang X, Huang R, Hu H. Real-world safety profile of etelcalcetide in dialysis-related secondary hyperparathyroidism: a pharmacovigilance analysis of FAERS data. — Renal Failure, 2025. DOI 10.1080/0886022x.2025.2523575.Could not be opened: Taylor & Francis Online returned a 403 error on every fetch attempt (publisher landing page, PDF, and DOI redirect all blocked). Listed only, not used as evidence.
  16. Cinacalcet-mediated activation of the CaMKKbeta-LKB1-AMPK pathway attenuates diabetic nephropathy in db/db mice by modulation of apoptosis and autophagy. — Cell Death and Disease, 2018. C57BLKS/J db/db mice, n=8/group, cinacalcet 10 mg/kg in diet, 12 weeks. DOI 10.1038/s41419-018-0324-4. Independently opened and re-verified for this revision (not cited secondhand from the companion cinacalcet dossier): confirmed the CaMKKbeta/PGC-1alpha effect is reversed by the intracellular calcium chelator BAPTA-AM and is framed by the authors as a broader calcimimetic/CaSR-class mechanism, not unique cinacalcet chemistry. Used here as the class-level lead for Mitochondrial burden and ATP production.
  17. Cinacalcet perturbs membrane permeability of bEND.3 endothelial cells and suppresses cell proliferation. — In vitro study, mouse brain microvascular endothelial cell line, cinacalcet 10-30 uM. PMID 41329537. Independently opened for this revision and confirmed the cytotoxic/mitochondrial-depolarization effect is unaffected by NPS 2143 (a CaSR negative allosteric modulator), i.e. CaSR-independent; checked and excluded as a class-level lead for etelcalcetide on that basis.
  18. Diri H, et al. Cinacalcet may improve oxidative DNA damage in maintenance hemodialysis patients: an observational study. — International Urology and Nephrology, 2014. n=42 cinacalcet-treated patients vs 38 matched controls, 6-month follow-up. PMID 24811568, DOI 10.1007/s11255-014-0723-0. Independently opened for this revision via an open-access repository copy; the authors attribute the benefit to "the direct action of cinacalcet" rather than PTH decrease, without resolving whether that action is CaSR-receptor-mediated or specific to cinacalcet's own structure.
  19. Treatment based on cinacalcet reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism. — Nephron, 2018. n=58 hemodialysis patients with sHPT, before/after 6-month observational design. PMID 29879701. Abstract independently re-opened for this revision: antioxidant-capacity change correlated with cinacalcet dose (r=0.30, p=0.02) but not with PTH change, ruling out simple PTH-mediation but not distinguishing a CaSR-receptor-generic mechanism from cinacalcet-specific chemistry.
  20. Schlingmann KP. Calcium-Sensing Receptor and Magnesium. — Book chapter, 2007. DOI 10.1007/978-1-84628-483-0_22. Established, receptor-level (not drug-specific) physiology reference confirming CaSR's role in renal tubular magnesium handling; used as class-generic mechanism support for the Magnesium entry.
  21. Toka HR, Pollak MR, Houillier P. Calcium Sensing in the Renal Tubule. — Physiology, 2015. DOI 10.1152/physiol.00042.2014. Established, receptor-level (not drug-specific) physiology review; confirms CaSR expression and function in the thick ascending limb governing paracellular calcium and magnesium reabsorption.
  22. Crossref API queries for etelcalcetide + copper, etelcalcetide + iron/ferritin/hepcidin, etelcalcetide + gut microbiome/microbiota, etelcalcetide + mitochondria, etelcalcetide + oxidative stress, etelcalcetide + magnesium, etelcalcetide + ATP/energy metabolism, etelcalcetide + hyperkalemia/potassium, and etelcalcetide + testosterone/reproductive; PubMed search-listing queries for etelcalcetide + magnesium and etelcalcetide + (oxidative stress OR mitochondria OR ATP). — Bibliographic search only (api.crossref.org, pubmed.ncbi.nlm.nih.gov), used to confirm the absence of drug-specific literature for the Ungraded entries and for the four categories re-researched in this revision (Magnesium, Mitochondrial burden, Oxidative stress, ATP production), before class-level leads were pursued instead. Not a citable study; recorded here for audit transparency.